Trading Summary - January 13. A satisfactory status quo

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
208
Trading Summary - January 13.

A satisfactory status quo day for $SFLM in the same bottom range - less than 25% of target price .02+ range (ie anything under .0052) - while OTC market top traders needed to concentrate elsewhere all day on multiple moves and loading opportunities on Watch List tickers $DGWR $INQD $BRGO $PSRU $ENZC.

On $SFLM, the attempts by the scammer to walk down the ask continued as reported contemporaneously.

All day there was further jockeying for position in the .0018 > .0025 range with buys on both the bid and the ask by traders looking to increase their overall inventory of shares for the expected move into the .01 > .02+ range ahead.

By the close, a few followers stepped up to add 2M to the bid at .0018, take out .0019s and start the .0020s again.

Notable buys today were 2M+ at .0021, 1M+ at .0020 and 2M + 1.8M at .0019.

None of the asks are of any significance to hinder a quick break above .0030 towards the .01 > .02 range needed for OTCQB uplisting - and as appropriate to its $10.241M revenue market cap - whenever the top traders of $SFLM decide to concentrate on it.

As shown in the report for December 31, 2021, the vast majority of shares are held with a cost basis under .0052 now with the balance above held by longs who didn't sell for a tax loss as it is self-evident the price should be going above .02 at some point in 2022.

Overall, 9.8M shares were bought today - all in the .0018 > .0022 range.

New interest traders / alerters + long-term traders with significant followings as at January 9 numbered at least 157 - up another 9 in the previous 7 days. List here:

https://investorshangout.com/post/view?id=6317433

Particular points they like are:

- Real revenue of $10.241M in 2021.

- Revenue growth of 34.75% in 2021 - beating the target of 30%.

- Operating profit achieved in Q3.

- $49K in cash available for inventory purchases at end-Q3.

- Assets of $1.398M at end-Q3.

- Low Unrestricted O/S of 837M - with none added in the last 3+ months.

- How thin it is into the .01 > .02 range.

- Multiple catalysts ahead throughout 2022.

On the next run over .01, the degree to which $SFLM penetrates up towards .02+ will depend on how many of these new followers take profits above .01.

Either way, longs who follow my strategy will be keeping their core holding for the OTCQB uplisting - which will require sustaining prices above a .01 bid - and also some for when all 9 elements reach the same revenue level anticipated by the CEO. Trading some on every surge allows a larger core to be held on a cost basis that is essentially "free" - already paid for by banked profits.

The correct market cap price for the anticipated revenue as income ramps up under the Collectibles Marketplace Strategy would be in the .063 > .1100 range in future years when they manage to get all 9 elements in the plan to the performance level of the existing SFLMaven eBay business (plus remember more platforms coming as well).

On $SFLM, the larger the inventory of shares acquired below .0050, the more that will be available to trade for 100% to 400% in the .01 > .0150 range on the next run to that level - whenever that may be - whilst also retaining a significant core converted to free f or OTCQB uplisting and the planned 8 x 2021 revenue under the Collectibles Marketplace Strategy.

Remember that the price difference between .0020 and .0050 is irrelevant when traded at .01 > .02+ - let alone at .063 > .1100.

Every 1M bought at .0050 is worth a $7K profit at .0120, $10K profit at .0150, $15K profit at .02, $57K profit at .074 or $102.5K profit at .1075.

All that matters is who got where - charts are irrelevant - and denying as many shares under .01 as possible to the institutional level new interest that PRs + improving financials + MZ Group though investor symposiums are expected to bring in over the days, weeks and months ahead in 2022.

Latest DD - updated January 9 - here:

https://investorshangout.com/post/view?id=6317446

$SFLM was the #1 Top Profit Pick and #1 Top Banked Profit stock of 2021 on my Watch List.

It is the joint #1 Top Profit Pick for the whole of 2022 (with $ENZC).

I will not necessarily be doing a trading summary every day - unless there are undue manipulation attempts - as the ticker is firmly under control and just awaiting the next run into the .01 > .02 range.

iHub has been deliberated marginalized due to time-wasting nonsense there with all serious interest successfully directed to here over the last several months - with typically 500 > 700+ views per day - and repeated where interest in "real" companies is known to exist.

Watch for the next PR which I would expect to cover the excellent Q3 results, the sales since in Q4, acquistions of collectibles companies and expansion of the NFT Division with artists recruited Nationwide.

The Share Structure was updated after the close on January 3 - again showing no change and confirming no dilution for 3+ months - with the Unrestricted O/S remaining at a low 837M.

2022 Week 1 revenue was $228K which equates to a pro-rata annual revenue of $11.888M.

Next auction is this evening - advance sales at "Buy It Now" this week are already almost $25K.

https://www.ebay.com/sch/i.html?_sofindtype=0...=1&rt=

SFLMaven, Inc. (SFLM) Stock Research Links

SFLM Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 234

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
TCL Tablets Arrive on BestBuy.com: What It Means

Updated Category News Views 11

Go Big or Go Home: TCL's Bold Move TCL just dropped a little bombshell that's gonna ripple through the electronics retail market—its tablets and smartphones are now bright and shiny on BestBuy.com. It's like standing at the craps table and before you know it, the stakes have just doubled. Why? Best Buy ain't some hole-in-the-wall spot. It's the premium electronics...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 345

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Formation Unveils First Solana Tokenized Securities Venue

Updated Category News Views 22

Well, here we go. Formation Securities is setting sail on the high seas of blockchain, aiming to operate a tokenized securities venue (TSV) on Solana. This isn't your garden-variety launch—it's a bold leap into a newer, faster-paced world of trading. Sure, you’ve heard about blockchains before, but this operation marries the traditional rigmarole of the stock market...

Continue Reading
Continuous Insulation Market Grows, Hits $67.74B by 2031

Updated Category News Views 19

Market Trends and Key Drivers Imagine riding a slow but steady bull market in insulation—sounds mundane, but the numbers don't lie. MarketsandMarkets™ had the scoop, predicting the Continuous Insulation Market will balloon from USD 56.98 billion in 2026 to USD 67.74 billion by 2031, putting down roots with a 3.5% CAGR. Now, you and I both know that when real estate...

Continue Reading
Tigo Energy Faces Class Action: Investor Deadline Looms

Updated Category News Views 5

Unpacking Tigo's Rollercoaster: Lawsuit & Market Reaction They sometimes say, "When it rains, it pours." For Tigo Energy, it’s been more a downpour than a drizzle. Here we are, chasing down what's going on with Tigo Energy (NASDAQ:TYGO), fresh off the heels of a class action fuss that's grabbed every investor's attention. If you've got a stake, or even a passing...

Continue Reading
O-I Glass Faces Class Action: Investor Implications

Updated Category News Views 130

O-I Glass in Hot Water Over Misleading Statements I'll tell you, nothing gets my goat quite like uncovering deceptive practices in the corporate world. It seems O-I Glass, Inc. (NYSE: OI), might have played a fast one with its shareholders. The company is staring down the barrel of a class action lawsuit from Schall, Brown & Schwartz LLP, alleging they weren't entirely...

Continue Reading
Photocure Navigates AssureMDx's Medicare Journey

Updated Category News Views 99

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Continue Reading
AWS Boosts Agilix's AI Education in Sierra Leone

Updated Category News Views 99

Agilix Labs' Landmark Leap with AWS Just when you think you've got the grip on global education dynamics, a new wave hits your shores, this time courtesy of Agilix Labs and AWS. Agilix Labs snagged a grant from Amazon Web Services, carving a path that blends AI with educational equity in Sierra Leone. Now, if that doesn’t prick up investor ears or yank a few...

Continue Reading
Zabalafin Hydrogel: Promise in Treating Atopic Dermatitis

Updated Category News Views 7

Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...

Continue Reading

Top 5 Most Recently Viewed Articles

Advantech Ups the Ante in Robotics with GMSL Cameras

Updated Category News Views 299

Breaking Down Barriers in Robotics Vision Forget the robots of old; today’s machines need eyes sharper than a hawk just to keep up with the competition. Advantech (TWSE: 2395) isn’t just watching—they’re leading the pack with their GMSL Camera Enablement Scheme. They’re accelerating robotics from Autonomous Mobile Robots (AMRs) to humanoids, and it’s about...

Continue Reading
Exploring New Gold Opportunities at Labrador Gold's Hopedale Project

Updated Category News Views 131

Exploring New Beginnings at the Hopedale Gold Project The excitement in the mining sector continues to grow as Labrador Gold Corp. (TSX-V: LAB | OTCQB: NKOSF | Frankfurt: 2N6) embarks on its 2025 exploration journey at the Hopedale Gold Project. With a dedicated field crew now mobilized, the company is ready to explore this promising gold-rich terrain located within the...

Continue Reading
OTCQB Venture Virtual Investor Conference Unveils Agenda

Updated Category News Views 149

OTCQB Venture Virtual Investor Conference Overview The OTCQB Venture Virtual Investor Conference is set to take place on August 7, offering a unique platform for investors to engage with innovative companies. Who Should Attend? This event is open to individual investors, institutional investors, advisors, and financial analysts eager to explore emerging opportunities....

Continue Reading
DAiM Invests in Fetch.ai to Enhance AI and Blockchain Synergy

Updated Category News Views 257

DAiM's Bold Step into the Future with Fetch.ai DAiM, a pioneering crypto wealth management firm located in Florida, is thrilled to share its new strategic investment in Fetch.ai, a standout project that merges artificial intelligence (AI) with blockchain technology. This innovative combination is aimed at streamlining data sharing and automating various processes, thereby...

Continue Reading
Atlantic American Corporation Experiences Notable Stock Decline

Updated Category News Views 180

Atlantic American Corporation Stock Hits a New Low In a tough market, Atlantic American Corporation (AAME) has recently hit a 52-week low, with its stock priced at $1.43 USD. This notable decline highlights a period of bearish sentiment for the insurance holding company, which has seen its share value drop by 17.18% over the past year. Investors are closely watching the...

Continue Reading